AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 142 min read$HURA

TuHURA Biosciences, Inc./NV (HURA): Results of Operations and Financial Condition

TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001498382 TuHURA Biosciences, Inc./NV 0001498382 2026-08-14 2026-08-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earlies

Original reporting
SEC EDGAR 8-K
Published Aug 14, 2026, 11:50 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$HURA
Neutral
low confidence
Mentioned
$HURA
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HURANeutralLow
01

Why it matters

The filing itself is a catalyst for investors to review the attached Exhibit 99.1 for updated financial performance and any corporate developments that could affect valuation and risk.

02

Market read

This is a routine but time-sensitive disclosure that can drive short-term repricing once the market digests the specific quarterly metrics and any update details.

03

What to watch

Traders should focus on the actual Exhibit 99.1 content (revenue, net loss, cash runway, financing needs, and any forward-looking statements), which is not included in the scraped text.

Relevance 7/10Novelty 3/10Timing: Filed today, with Exhibit 99.1 press release dated August 14, 2026.

Background

The article is an SEC Form 8-K (Item 2.02) for TuHURA Biosciences, Inc., referencing a press release with quarterly results and a corporate update.

Company-level read

Ticker impact

$HURANeutralLow confidence
Context

TuHURA filed an 8-K stating it issued a press release with financial results for the three months ended June 30, 2026.

Expected impact

Potential near-term volatility around the attached Exhibit 99.1 details, but the provided text does not include the actual numbers or guidance.

Evidence & confidence

The body confirms the filing and that Exhibit 99.1 contains results and an update, but it does not provide the financial figures, cash position, or any explicit guidance changes.

Market effects

Sector

No sector-level implications are disclosed in the provided text beyond a routine quarterly reporting event.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If Exhibit 99.1 contains only routine updates with no guidance or cash-flow surprises, the trading impact may be limited despite the filing.

Key entities

  • issuer
    TuHURA Biosciences, Inc.

    Company filing the 8-K and issuing the attached press release with quarterly results and a corporate update.

  • executive
    Dan Dearborn

    CFO signing the 8-K.

Read at source← All news

Related articles

AUG 14
$HURAMedAI 8/10

TuHURA Biosciences, Inc.: TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences (NASDAQ:HURA) reported Q2 2026 results for the quarter ended June 30, 2026, and outlined upcoming FDA and clinical milestones. Cash was $1.0M at June 30. R&D expenses were $6.6M. The company also described a $50M non-convertible term credit facility from its largest shareholder and expected orphan drug designations and trial starts in 2H 2026-2027.

finanznachrichten.de6 min
AUG 21
$ZIMMed

Zim profit rises on Q2 revenue of $1.78 billion

Zim reported Q2 revenue of $1.78 billion and reaffirmed its 2026 guidance for adjusted EBITDA of $2 billion to $2.4 billion and adjusted EBIT of $700 million to $1.1 billion. The company expects to pay a dividend based on 2026 results. The proposed merger with Hapag-Lloyd is pending regulatory approvals, despite opposition from Israeli agencies.

yahoo.com2 min
AUG 21
$ONDSMedAI 8/10

High Growth, High Cash Burn: Decoding the Split Narrative on Ondas (ONDS)

Ondas (ONDS) reported Q2 revenue of $83.8M, up 67% sequentially and 85% YoY organically. The company raised full-year guidance to $525M-$550M and expects a $1B annualized run rate by year-end. However, it also posted a $51M adjusted EBITDA loss and warned of margin pressure. The stock is polarizing, with high institutional ownership and significant short interest.

insidermonkey.com3 min
AUG 21
$ASNDMedAI 8/10

Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine

Ascendis Pharma (ASND) reported Q2 revenue of €315M, up from a year earlier, with all three TransCon therapies contributing. YORVIPATH reached blockbuster status, SKYTROFA had 20,000 patient enrollments, and YUVIWEL launched with €8M in sales. Costs rose, with SG&A and R&D expenses increasing. Operating profit included a one-time gain. The company has €812M in cash and no debt.

yahoo.com2 min
AUG 21
$HTHTMedAI 8/10

H World (HTHT) Approved a $2.5 Billion Return Plan. Is Growth Being Sacrificed?

H World Group (HTHT) shares rose 11.3% after Q2 results showed 13.2% hotel turnover growth and 10.8% revenue increase. The company raised 2026 revenue growth forecast to 4%-8% and approved a $2.5B return plan. It operates 13,539 hotels with 1.34M rooms and has 3,089 hotels in pipeline. Cash reserves were RMB14.2B against RMB4.2B debt. The board declared a $275M dividend.

yahoo.com2 min